Monthly Archives: May 2008

Monkeys, Robots and the University of Pittsburgh – New hope for paralysis victims?

The day after Tom Holder spoke at the University of Pittsburgh about the importance of animal research, more news is coming from this academic institution.

Every 45 seconds someone in the US gets a stroke, many are left paralyzed, furthermore 14,000 people every year suffer spinal cord injuries which may also result in paralysis. There is therefore huge incentive to learn how to bypass the damaged parts of the brain by a brain-machine interface so that the patients can regain effective movements that would be a huge help in their daily lives. It is not surprising that there has been widespread press coverage of a study published online in Nature yesterday (1) that signalled a major breakthrough in this field.

http://www.nytimes.com/2008/05/29/science/29brain.html?hp
http://www.washingtonpost.com/wp-dyn/content/article/2008/05/28/AR2008052802814.html

Using 2 rhesus monkeys Andy Schwartz and his team at the University of Pittsburg have made a huge advance towards that aim. They trained the monkeys to use their own motor cortical activity to control a mechanized arm to feed themselves. The team extracted the control signal from recording from about 50 nerve cells in the animals’ motor cortex. This was far fewer neurons than many researchers thought would be necessary, an important discovery in itself that should make it a little easier to design electrode implants in future. Once the monkeys got used to the system they soon became astonishingly fluid, skilled and expert in moving the robot arm just by altering the firing of their motor cortical neurones. They even learnt to take advantage of the marsh mallows sticking to the robot fingers to speed its delivery to their mouths. Even though clinical use for people with disabilities is still years away because the arm requires large computers, bulky equipment and a full time technician, and the brain-implanted electrodes would not last a lifetime and lack touch feedback from the arm, Schwartz’s achievement is phenomenal and a huge leap towards helping all those people with paralysis.

It is important to emphasise that this work could not have taken place without many years of animal experiments, with monkeys playing a key role (2,3). Andy has been working with monkeys trained to make movements designed to reveal how the motor cortex works for some 20 years. Only monkeys have the kind of control over their hands that we have, so only using monkeys could he work out the kind of control signals that they use to feed themselves. 20 years of monkey experiments (only using 1 or 2 a year) allowed him to ‘take the system to pieces’ and work out how the motor cortical cells control the arm. Obviously these experiments couldn’t be done on humans, they are simply too risky at this early stage in the development of the technology, but now he’s elucidated the control circuitry it will not be long before they’ll be applied to benefiting paralysed humans.

Kind regards,

John Stein

Professor of Physiology, Magdalen College, Oxford University
1) Velliste M. et al. “Cortical control of a prosthetic arm for self-feeding” Nature. 2008 May 28. [Epub ahead of print]

2) Lebedev M.A. and Nicolelis M.A.L. “Brain–machine interfaces: past, present and future” Trends in Neurosciences Volume 29, Issue 9, Pages 536-546 (2006)

3) Schwartz A.B. et al. “Brain-Controlled Interfaces: Movement Restoration with Neural Prosthetics” Neuron Volume 52, Issue 1, Pages 205-220 (2006)

SR in Pittsburgh

A diverse audience of approximately fifty researchers, animal care technicians and medical students, both undergraduates and postgraduates, attended the Speaking of Research presentation at Pittsburgh University. From “Science for the Non-scientist, a lesson in getting your message across” (summarized in our YouTube video), to “Pro-Test: the UK experience of the animal rights issue”, and finally approaching the big question of “What can you do?”, Tom Holder provided information, ideas and reflections on a wide range of issues relating to animal research.

It was good to see student neuroscientists and other undergraduate researchers, working towards a better understanding of diseases including Parkinson’s, Alzheimer’s and behavioral disorders such as ADHD (Attention-Deficit Hyperactivity Disorder). Already these students were learning about the crucial role which animals play in modern medicine.

Regards

Tom

A monkey model of Huntington’s disease

Huntington’s disease is an inherited neurological disease that affects about 30, 000 Americans and for which there is no effective treatment or cure.  An important step to developing new treatments was announced last week when scientists at the Yerkes National Primate Research Center in Atlanta published a paper (1) describing how they genetically modified monkeys to carry the defective huntingtin gene (the mHtt gene) that causes the disease.  This is the first time that monkeys have been genetically modified to have a human disease and the achievement of Dr. Anthony Chan and his colleagues has received widespread news coverage.

http://www.abc.net.au/science/articles/2008/05/19/2249028.htm
http://www.msnbc.msn.com/id/24695078/

In the past few years research using a range of transgenic organisms, including flies, nematode worms and mice, has made important contributions to our knowledge of how the mHtt gene causes Huntington’s disease (2), and transgenic models have also been vital to the evaluation of potential treatments (3). These models do not however fully replicate the cognitive deterioration and behavioral problems that are associated with Huntington’s disease, and can’t be used to study all of the changes that occur in different tissues as the disease slowly progresses. The genes, physiology and lifespan of monkeys are far closer to that of humans, so it is hoped that a monkey model of Huntington’s disease will provide new insights into the development of the disease to complement and confirm the observations made using more distantly related species.  The monkey model will also play an important role in the preclinical testing of new treatments for Huntington’s disease, since their effect on cognitive abilities can be more readily assessed.

It is important to note that this is just a first step to the development of a monkey model of Huntington’s disease, further refinement will be necessary before it is ready for use in research.  Other organisms such as flies and mice will continue to account for most animal research into Huntington’s disease.  Nevertheless Speaking of Research congratulates Dr. Chan and his team on their success so far.

In related news Dr. Antony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said that the National Institute of Health (NIH) is planning for a significant increase in primate research as the focus in HIV research shifts to studies aimed at getting a better understanding of how the disease infects its victims and progresses to AIDS (4). We are glad to hear that the NIH is consulting with scientists and drawing up plans to facilitate this important work at its National Primate Research Centers.

Regards

Paul Browne

1) Yang S.H. et al. “Towards a transgenic model of Huntington’s disease in a non-human primate.” Nature. 2008 May 18. [Epub ahead of print].

2) Sipione S. and Cattaneo E. “Modeling Huntington’s disease in cells, flies, and mice.” Mol Neurobiol. Volume 23(1), pages 21-51 (2001).

3) Harper S.Q et al. “RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model.” Proc. Natl. Acad. Sci. USA Volume 102(16), pages 5820-5825 (2005).

4) “US plans more primate research” Nature Volume 453 (7194), page 439 (2008) http://www.nature.com/news/2008/080521/full/453439a.html

SR in Pittsburgh – May 27th

On Tuesday, May 27th 2008, Speaking of Research founder, Tom Holder, will be speaking at Pittsburgh University (Note to self: Pittsburgh does not rhyme with Edinburgh). The presentation will take place at: S100a, Biomedical Science Tower (map).

The order of the day is:

4:00 – 4:30 pm Introductions
4:30 – 5:30 pm Seminar
5:30 – 6:00 pm Questions

There’s even a neat little flier you can distribute to your friends.

So come and listen about how you can (and indeed why you should) stand up for life-saving research, as well as the story of Pro-Test, and how it helped change the terms of the animal rights debate in England.

Regards

Tom

Updating the Website

The website has been undergoing some minor updates over the last few days.

We now have not one, but two web addresses. Both www.speakingofresearch.org and www.speakingofresearch.com will take you to this website. Equally all e-mail addresses should work in either the .org or .com form.

Check the (new) Calendar tab to see past and future presentations by Speaking of Research, clicking on past events will take you to the relevant blog/news post. Keep checking back for any updates (Information about an upcoming talk at Pittsburgh can be found there).

For those people wanting to give their own presentations on the science behind animal research, we have some basic presentation slides available on the website for you to download. Try and use these in conjunction with your own slides (entire slides can be copied and pasted between Powerpoint presentations)

The Speaking of Research YouTube presentation has been a huge success with almost 1,000 views in 10 days. So tell your friends about it, and remember to rate, favorite and comment on it.

We want your suggestions on how to improve the website – so email contact@speakingofresearch.org and tell us what you would like to see added to the website.

Regards

Tom

A vaccine against meningitis B?

Newspapers in the UK are buzzing with excitement over news that a new vaccine against meningitis B developed by the Swiss pharmaceuticals firm Novartis has performed well in early clinical trials.

http://www.guardian.co.uk/society/2008/may/15/health.medicalresearch
http://www.independent.co.uk/life-style/health-and-wellbeing/health-news/meningitis-defeated-at-last-828286.html

About 3,000 mostly young people catch meningitis B every year in the USA, of whom about 10% die and 25% suffer lifelong injuries, so an effective vaccine is highly desirable.  Until now efforts to prevent meningitis B have been hampered by the fact that existing vaccines only protect against a few of the numerous different type B strains of the bacterium Neisseria meningitidis that cause the disease, so the development of a universal vaccine that is potentially effective against a wide range of bacterial strains is a significant advance (1).

The development of the new vaccine is also noteworthy because of how it was done.  Vaccine development relies on identifying parts of the bacterium known as antigens that can act as targets for the immune system. Rather than using the usual method of attempting to isolate bacterial protein that might act as antigens the Novartis team led  by  Dr. Mariagrazia Pizza adopted a “reverse vaccinology” approach where they searched the Neisseria meningitidis genome for genes that encoded proteins that might be useful antigens.  They identified over 300 potential antigens, and the next step was to screen these for their ability to stimulate the immune system to produce antibodies that kill bacteria in vitro.  This required an intact functioning mammalian immune system, so the researchers used mice (2).

The mice were injected with candidate antigens and later antibodies were harvested from the mice and tested for their bactericidal activity against three distinct strains of Neisseria meningitidis, identifying twenty eight antigens that induced the production of bactericidal antibodies. However none of these 28 antigens were potent enough to be used alone in a universal vaccine, so the researchers next assessed various combinations of the most promising antigens.  A vaccine containing 5 antigens  was found to induce the production of antibodies that had excellent bactericidal activity against all three strains of Neisseria meningitidis.  The multicomponent vaccine was then tested against a panel of 85 type B Neisseria meningitidis strains that represent the global diversity of the bacterium, and was found to be effective against almost all strains, especially the most lethal strains.  To check that the bactericidal activity in vitro correlated to an ability to prevent disease rats which had been infected with Neisseria meningitidis were treated with serum containing antibodies from vaccinated mice. Rats that were treated with serum were fully protected, a result that provided good evidence that the multicomponent vaccine works.

This vaccine has now been assessed in human trials involving 150 children, and found to safely stimulate the production of antibodies that kill Neisseria meningitidis.  Of course it still remains to be determined if this vaccine does protect against a wide range of  meningitis B strains in the field, and larger clinical trials to evaluate this are underway, but the results so far are very promising.

Cheers

Paul Browne
1) Novartis press release, May 14 2008. http://www.novartis.com/newsroom/media-releases/en/2008/1218899.shtml
2) Giuliani M.M. et al. “A universal vaccine for serogroup B meningococcus” Proc Natl Acad Sci U S A. Volume 103, Issue 29, pages 10834-10839 (2006).

North Carolina: Day 2: UNC-Chapel Hill

After a successful day on the Duke University campus (see previous post), I headed over to the Smithies & Maeda’s Laboratories in the Department of Pathology and Laboratory Medicine at the University of North Carolina – Chapel Hill. Here I gave a presentation to Nobel Prize Laureate (For his work in introducing gene modifications into mice through embryonic stem cells, 2007) Oliver Smithies, and the members of his lab. After finishing, it was back to work for Smithies and his colleagues, but not before I had managed to get a quick photo. Tom meets Nobel Prize Laureate Oliver Smithies

Later that day I headed to the Medical Biomolecular Research Building to give a talk to researchers, animal care technicians, and even a couple of animal activists who turned up. The presentation went well (despite finding myself continually blinded by the projector light while walking across the stage), and afterwards the two animal rights activists dominated the questions – who appeared disappointed to find that as a student of philosophy I could deconstruct their Benthamite (“Not can they reason, but can they suffer”) philosophy on rights (see AR beliefs section of website)

If you would like to see Speaking of Research talk at your institution, go to Request a Speaker.

On a final, and entirely separate note, the Pro-Test Facebook Group recently passed 3,000 members – Let’s hope the Speaking of Research Facebook Group can do the same.

Regards

Tom

Speaking of Research – In North Carolina

I’ve been in North Carolina since Monday night, having already given a couple of talks at Duke University earlier today, and popped my head into an AALAS meeting. The reception has been warm at all events, with Duke going as far as to offer AALAS credits for any animal researchers, technicians and veterinarians who went to my midday talk (which was well attended – partly due to the AALAS credits on offer, partly due to interest in the talk, and partly due to the free cake!)

Tomorrow (May 14th), I am speaking in 3:30pm at the Molecular Biology Research Building, room 2204, on UNC Chapel Hill campus (see here). My talk will cover a number of areas, and I would encourage people to look at this lovely promotional piece, regarding my talk.

On a separate note, keep favoriting, and rating the Speaking of Research YouTube video, which has over 700 views (in 5 days) and is moving up the weekly “Top Favorite” and “Top Rated” awards for Videos in the Science and Technology section.

Regards

Tom